Latest Breaking News On - Adverse cardiac events - Page 1 : comparemela.com

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Scott harrisDanielle ducheneVipink gargExchange commissionAltimmune incAnnounces positive topline resultsWeek phaseChief medical officerChief executive officerCochran mantel haenszelAdverse cardiac eventsInvestor relationsCall detailsPrivate securities litigation reform act

Altimmune (ALT) Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Altimmune (ALT) Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Scott harrisVipink gargAltimmune incChief medical officerChief executive officerCochran mantel haenszelAdverse cardiac eventsCall informationaltimmuneInvestor relations

Bristol Myers Squibb s First Disclosures and New Data at ASH 2023 Highlight Company s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.

United statesSan diegoSikander ailawadhiFrancesco passamontiLisocabtagene maraleucelGuillaume cartronRavi vijMaroof hasanMark kaplanRachid bazHemophagocytic lymphohistiocytosisDanny jeyarajuSheida hayatiSusan balSamit hirawatFranck morschhauser

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of. | May 11, 2023

United statesSouth koreaAndrew weiBartl scottJean marie michotLorettaj nastoupilNizarj bahlisMitsuho imaiJohn mascarenhasAmit vermaKevin joseph harringtonDavid paul carboneHemophagocytic lymphohistiocytosisHeinz josef lenzFarrukh awanHusseina tawbi

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant .

United statesSouth koreaAmit vermaSaloman manierAlit taherAndrew weiHemophagocytic lymphohistiocytosisBartl scottJonathan spicerPaul david harker murrayHaifa kathrin al aliJavier munozJavidj moslehiKrina patelFarrukh awanRafat abonour